Work

Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.tps595

Authors: Rohit K. Jain, Youngchul Kim, Jennifer Rembisz, Richard Piekarz, Timothy W. Synold, Jingsong Zhang, Guru P. Sonpavde

Institutions: Moffitt Cancer Center, National Cancer Institute, City Of Hope National Medical Center, Dana-Farber Cancer Institute

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4213200322

Cites:

Cited by: 12

Related to: 10